Improvita Celebrates ZELSUVMI™ FDA Approval for the Treatment of Molluscum Contagiosum

MADISON, Wis., January 25, 2024 — Improvita, Inc., a Madison-based company affiliated with Innovenn, Inc., that focuses on human factors testing, ethnographic field research, user interface and user experience testing for medical devices, software as a medical device (SaMD), and combination drug/medical device products, is pleased to announce that its partner, Ligand Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval for ZELSUVMITM (berdazimer topical gel, 10.3%). The medication was approved on January 5, 2024 for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older.

Improvita’s full-service Human Factors Validation testing was used as part of the New Drug Application (NDA) for ZELSUVMI. The Improvita team was honored to partner with  Ligand on this important initiative to bring this first and only topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician’s office, or other medical setting, to FDA approval.

To learn more about Improvita’s commitment to bringing innovative healthcare solutions to life, please visit www.improvita.com or www.Innovenn.com or email our CEO at maryd@innovenn.com.